On April 27, 2026, ZonhonBio's independently developed Class 1 novel biologic drug ZHB117 sublingual tablets, which holds full intellectual property rights both domestically and internationally, received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration (NMPA). The newly approved indication covers desensitization therapy for allergic rhinitis or rhinoconjunctivitis (with or without allergic asthma) caused by cat allergen sensitivity in pediatric patients aged 3 to 17 years.